Whitehawk Therapeutics (WHWK) Return on Capital Employed (2011 - 2026)
Whitehawk Therapeutics (WHWK) reported Return on Capital Employed of 9.87% for Q1 2026, up 3529.0% year-over-year from 0.27% in Q1 2025, and down 229.49% on a QoQ basis from 3.0% in Q4 2025.
Whitehawk Therapeutics (WHWK) has 16 years of Return on Capital Employed data on file, last reported at 9.87% in Q1 2026.
- Quarterly Return on Capital Employed rose 3529.0% year-over-year to 9.87% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9.87% (up 3529.0% YoY) and the FY2025 annual result came in at 4.5%, up 7552.0% from the prior year.
- Return on Capital Employed retreated to 9.87% in Q1 2026 per WHWK's latest filing, from 3.0% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 3.0% in Q4 2025 and bottomed at 110.71% in Q4 2024.
- The 5-year median for Return on Capital Employed is 55.79% (2023), against an average of 59.68%.
- The widest annual swing landed in 2022, when Return on Capital Employed slumped 12641 bps; it then surged 10771 bps in 2025.
- Tracing WHWK's Return on Capital Employed over 5 years: stood at 36.8% in 2022, then slumped by 78 bps to 65.6% in 2023, then plunged by 69 bps to 110.71% in 2024, then soared by 97 bps to 3.0% in 2025, then sank by 229 bps to 9.87% in 2026.
- Per Business Quant, the three latest WHWK Return on Capital Employed figures stand at 9.87% (Q1 2026), 3.0% (Q4 2025), and 66.11% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Whitehawk Therapeutics | 312.26 Mn | 189.22 Mn | - | -9.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.87% |
| Dec 31, 2025 | -3.00% |
| Sep 30, 2025 | -66.11% |
| Jun 30, 2025 | -51.51% |
| Mar 31, 2025 | -45.15% |
| Dec 31, 2024 | -110.71% |
| Sep 30, 2024 | -85.07% |
| Jun 30, 2024 | -83.92% |
| Mar 31, 2024 | -73.25% |
| Dec 31, 2023 | -65.60% |
| Sep 30, 2023 | -55.79% |
| Jun 30, 2023 | -45.20% |
| Mar 31, 2023 | -41.14% |
| Dec 31, 2022 | -36.80% |
| Sep 30, 2022 | -44.02% |
| Jun 30, 2022 | -110.21% |
| Mar 31, 2022 | -87.26% |
| Dec 31, 2021 | -75.11% |
| Sep 30, 2021 | -94.91% |
| Jun 30, 2021 | -5.99% |
| Mar 31, 2021 | 39.15% |
| Dec 31, 2020 | 254.87% |
| Sep 30, 2020 | -4.81% |
| Jun 30, 2020 | -11.92% |
| Mar 31, 2020 | -56.07% |
| Dec 31, 2019 | -62.02% |
| Sep 30, 2019 | -65.16% |
| Jun 30, 2019 | -25.63% |
| Mar 31, 2019 | -22.54% |
| Dec 31, 2018 | -18.13% |
| Sep 30, 2018 | -13.00% |
| Jun 30, 2018 | -119.77% |
| Mar 31, 2018 | -169.06% |
| Dec 31, 2017 | -107.36% |
| Sep 30, 2017 | -72.71% |
| Jun 30, 2017 | -58.99% |
| Mar 31, 2017 | -105.00% |
| Dec 31, 2016 | 121.81% |
| Sep 30, 2016 | 6,634.54% |
| Jun 30, 2016 | 4,213.96% |
| Mar 31, 2016 | 2,221.23% |
| Dec 31, 2015 | 11.94% |
| Sep 30, 2015 | 13.40% |
| Jun 30, 2015 | 14.61% |
| Mar 31, 2015 | 14.01% |
| Dec 31, 2014 | 16.12% |
| Sep 30, 2014 | 14.86% |
| Jun 30, 2014 | 16.18% |
| Mar 31, 2014 | 17.19% |
| Dec 31, 2013 | 18.82% |
| Sep 30, 2013 | 20.52% |
| Jun 30, 2013 | 20.23% |
| Mar 31, 2013 | 23.09% |
| Dec 31, 2012 | 23.83% |
| Sep 30, 2012 | 26.32% |
| Jun 30, 2012 | 30.09% |
| Mar 31, 2012 | 28.60% |
| Dec 31, 2011 | 35.61% |
| Sep 30, 2011 | 40.12% |